| Endocardial Solutions, Inc. (ESI) develops, markets, and distributes an advanced cardiac mapping system for the treatment of patients with rapid or abnormal heart rates. The EnSite 3000® System was first introduced to the European market in the second quarter of 1998. In April 1999, the system was approved for use in the U.S. by the FDA in the the right atrium of the heart. With 2001 sales of $22.9 million, Endocardial Solutions now has a presence in 25 countries worldwide. Endocardial Solutions' shares are traded on NASDAQ under the symbol ECSI. First quarter earnings report Endocardial Solutions invites you to participate in a teleconference call to discuss the fourth quarter and 2001earnings results on April 23, 2002 at 9:30am (CST). Jim Bullock, President and CEO, will lead the call. Please call the number listed below five minutes prior to the call. We look forward to your participation. Instant replay of this call will be available until 12:00 midnight (CST) on April 30, 2002. Endocardial Solutions, Inc.
First Quarter Earnings Conference Call
April 23, 2002
9:30am (CST)
1-877-272-5391
Moderator: Jim Bullock
Instant Replay through April 30th, 2002:
|
